MedTrace Logo

Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia

NCT01025388 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4053

Last updated 2013-02-08

No results posted yet for this study

Summary

The purpose of the study is to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the NCEP ATP III/updated 2004 NCEP ATP III guidelines, overall and by country, in the following sub-populations:

* Primary/secondary prevention patients.
* Patients with metabolic syndrome (according to NCEP III definition).

In addition, the purpose is to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the Third Joint European Task Force guidelines/national guidelines, in the survey population and in the following sub-populations:

* Primary/secondary prevention patients.
* Patients with metabolic syndrome.

Conditions

Sponsors & Collaborators

  • ClinArt Company & Signen Clinical Discoveries

    collaborator UNKNOWN

  • AstraZeneca

    lead INDUSTRY

Principal Investigators

  • Prof. Mohammed Arafah · King Khalid University Hospital

  • Dr. Shorook Alherz · King Fahad National Guard Hospital

  • Dr. Khalid Alnemer · Security Forces Hospital

  • Dr. Hossam Alghetany · Soliman Fakieh Hospital

  • Dr. Othman Metwally · King Fahad General Hospital

  • Dr. Akram Alkhadra · King Fahad University Hospital

  • Dr. Faisal Alanizi · Ministry of Health, Saudi Arabia

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2010-05-31
Completion
2010-05-31

Countries

  • Saudi Arabia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01025388 on ClinicalTrials.gov